In 70% of solid organ transplant patients, antibodies to SARS-CoV-2 were detected after completion of their three-dose vaccination, and therefore a clinical study with a fourth dose of this susceptible vaccine was performed in France. population.
37 patients were studied from 1 July 2021 to 5 August 2021, of whom 5 had a small antibody response to the previous 3 doses of the Pfizer vaccine and the rest had no antibodies at all despite the three doses. The Doctors of the Therapeutic Clinic of the Medical School of the National and Kapodistrian University of Athens Theodora Psaltopoulou, Panos Malandrakis, Giannis Danasis and Thanos Dimopoulos (Rector of EKPA) summarize the relevant article in JAMA magazine.
The first two doses were one month apart, the third dose was given 2 months after the second and the last dose was given 65 days on average after the third. The patients were 54% male and their mean age was 60 years. Neutralizing antibodies were detected in 5 subjects before the fourth dose (13.5%) and in 18 (48.6%) 1 month after the fourth dose. For the 5 patients who had a positive antibody titer before the fourth dose, this titer multiplied up to 10 times after the last dose of the vaccine.
Among the 31 patients who did not have antibodies before the fourth dose, 13 (41.9%) obtained a positive antibody titer 4 weeks after the fourth dose. A total of 4 weeks after the fourth dose, 86.5% of patients had an antibody titer below 140 BAU / ml, a titer corresponding to protection of only 12.4% in a group of healthy health professionals.
No serious adverse reactions were reported, other than fatigue and myalgia in 4 patients, in one patient gastrointestinal disorders and in one kidney transplant patient IgA renal disease recurred.
Follow Skai.gr on Google News
and be the first to know all the news
.
